Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC)

Leukemia Research

Volumn 26, Issue 5, 2002, Pages 477-482

  Hatta, Yoshihiro ^a   Itoh, Takeyoshi ^a   Baba, Masumi ^b   Miyajima, Tsuyoshi ^a   Shimojima, Hiromi ^a   Sawada, Umihiko ^a   Horie, Takashi ^a  

^a NIHON UNIVERSITY   (Japan)

^b Akiru Municipal General Hospital   (Japan)

Author keywords

4 HC; ATP; Autologous bone marrow transplantation; Cell membrane; L1210; Leukemia; Permeability; Purging

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ADENOSINE TRIPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL MEMBRANE; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; BONE MARROW PURGING; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; LEUKEMIA L1210; MALE; MICE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036201837     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00164-3     Document Type: Article

References (49)

1. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation for CML
2. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
3. Gene marking to trace origin of relapse after autologous bone marrow transplantation
4. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment
5. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma
6. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction
7. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin
8. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation
9. Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation
10. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: Results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement
11. Purging of mammary carcinoma of cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins
12. Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia
13. Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid cell-specific monoclonal antibodies
14. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroxyperoxycyclophosphamide
15. 4-Hydroperoxycyclophosphamide: A model for eliminating residual human cells and T lymphocytes from the bone marrow graft
16. Autologous bone marrow transplantation in acute leukemia: A phase I study of in vitro treatment of marrow with 4-hydroxycyclophosphamide to purge tumor cells
17. Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamide
18. Pharmacological purging of bone marrow with reference to autografting
19. Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid
20. Potential of phenylalanine methylester as a bone marrow purging agent
21. Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on hematopoietic rescue after high-dose therapy
22. Hematopoietic recovery in a patient with acute lymphoblastic leukemia after an autologous marrow graft purged by combined hyperthermia and interferon in vitro
23. Elimination of clonogenic tumor cells from HL-60, Daudi, and U-937 cell lines by laser photoradiation therapy: Implications for autologous bone marrow purging
24. Marrow purging by merocyanine 540-mediated photolysis
25. Studies on cyclophosphamide metabolites and their related compounds. II. Preparation of an active species of cyclophosphamide and some related compounds
26. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydeoperoxycyclophosphamide purged bone marrow
27. Autologous bone marrow transplantation in high-risk remission T lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroxyperoxycyclophosphamide for marrow purging
28. Variability in 4-hydrperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation
29. Effect of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow
30. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute non-lymphoblastic leukemia
31. Selective killing of murine leukemic cells by adenosine triphosphate (ATP): A study of the value of autologous bone marrow transplantation
32. Cytotoxic effect of extracellular ATP on L1210 leukemic cells and normal hematopoietic stem cells
33. External ATP-induced passive permeability changes and cell lysis of cultured transformed cells: Action in serum-containing growth media
34. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation
35. Extracellular ATP as a trigger for apoptosis or programmed cell death
36. Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages
37. Responses of mouse lymphocytes to extracellular adenosine 5′ triphosphates (ATP). Lymphocytes with cytotoxic activity are resistant to the permealizing effects of ATP
38. Ecto-ATPase activity in cytolytic T lymphocytes
39. Extracellular adenosine 5′ triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation
40. The effect of exogenous ATP on the electrolyte content of TA3 ascites tumor cells
41. Extracellular ATP4-promotes cation influxes in the J774 mouse macrophage cell line
42. Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes
43. Comparative in vitro effects of cyclophosphamice derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes
44. Demonstration of an ATPase at the cell surface of intact normal and neoplastic human cells in culture
45. Formation of extracellular adenosine triphosphate by normal and neoplastic human cells in culture
46. Nucleoside triphosphate activity at the external surface of neuroblastoma cells
47. 2+ stimulated adenosine triphosphate at the outer surface of Ehrlich ascites tumor cells
48. Divalent cation-activated ecto-nucleoside triphosphate activity of nervous system cells in tissue culture
49. Ecto-ATPase